Compare WVE & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | CENT |
|---|---|---|
| Founded | 2012 | 1955 |
| Country | Singapore | United States |
| Employees | N/A | 6000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2015 | N/A |
| Metric | WVE | CENT |
|---|---|---|
| Price | $7.26 | $35.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | $30.25 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 5.4M | 86.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | $0.34 | $1.60 |
| Revenue Next Year | $83.30 | $2.04 |
| P/E Ratio | ★ N/A | $15.73 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $28.77 |
| 52 Week High | $21.73 | $41.25 |
| Indicator | WVE | CENT |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 41.26 |
| Support Level | $6.94 | $34.74 |
| Resistance Level | $8.29 | $36.36 |
| Average True Range (ATR) | 0.75 | 0.95 |
| MACD | -0.50 | -0.10 |
| Stochastic Oscillator | 26.85 | 22.01 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.